within Pharmacolibrary.Drugs.ATC.L;

model L02BA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 27.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0055000000000000005,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Elacestrant is an orally bioavailable, nonsteroidal selective estrogen receptor degrader (SERD) used for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer. It is approved for clinical use in adults with ER+/HER2- breast cancer that has progressed after prior endocrine therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics were evaluated in adult patients with advanced ER+/HER2- breast cancer receiving oral elacestrant as monotherapy.</p><h4>References</h4><ol><li><p>Beumer, JH, &amp; Foldi, J (2023). Pharmacology and pharmacokinetics of elacestrant. <i>Cancer chemotherapy and pharmacology</i> 92(2) 157–163. DOI:<a href=&quot;https://doi.org/10.1007/s00280-023-04550-7&quot;>10.1007/s00280-023-04550-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37314500/&quot;>https://pubmed.ncbi.nlm.nih.gov/37314500</a></p></li><li><p>Bardia, A, et al., &amp; Kabos, P (2021). Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 39(12) 1360–1370. DOI:<a href=&quot;https://doi.org/10.1200/JCO.20.02272&quot;>10.1200/JCO.20.02272</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33513026/&quot;>https://pubmed.ncbi.nlm.nih.gov/33513026</a></p></li><li><p>Guglielmi, G, et al., &amp; Fogli, S (2024). Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer. <i>European journal of pharmacology</i> 969 176424–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejphar.2024.176424&quot;>10.1016/j.ejphar.2024.176424</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38402929/&quot;>https://pubmed.ncbi.nlm.nih.gov/38402929</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L02BA04;
